Loading...
01/11 11:30
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates several concerns: a sequential decline in revenue, lower clear aligner volume, and a decrease in gross and operating margins. Despite some positive aspects like non-GAAP net income growth and cost-saving measures, the overall guidance is weak, with sequential declines expected and no specific details on future improvements. The Q&A section also highlighted management's reluctance to provide specifics on key issues, which could erode investor confidence. These factors suggest a negative sentiment, likely leading to a stock price decrease of -2% to -8%.
Total Revenues $995.7 million, up 1.8% year-over-year and down 1.7% sequentially. The year-over-year increase was favorably impacted by approximately $15.6 million due to foreign exchange and higher Clear Aligner volumes.
Clear Aligner Revenues $805.8 million, up 2.4% year-over-year and slightly up sequentially. The year-over-year increase was driven by higher volume, price increases, favorable foreign exchange, and lower net deferrals, partially offset by higher discounts and product mix shift to lower-priced countries and products.
Clear Aligner Volume 648,000 cases, up 4.9% year-over-year and 0.5% sequentially. The year-over-year growth was driven by strong performance in APAC and EMEA regions, offset somewhat by North America.
Systems and Services Revenues $189.9 million, down 0.6% year-over-year and 8.6% sequentially. The year-over-year decrease was primarily due to lower scanner system sales, partially offset by higher scanner wand sales, higher nonsystem sales, and favorable foreign exchange.
Non-GAAP Operating Margin 23.9%, up 1.8 points year-over-year and 2.6 points sequentially. The increase was due to operational efficiencies and favorable foreign exchange.
Gross Margin 64.2%, down 5.5 points year-over-year and 5.7 points sequentially. The decrease was primarily due to restructuring and other noncash charges, impairment on assets held for sale, depreciation expense on assets to be disposed of other than by sale, and excess inventory write-off.
Net Income Per Share (GAAP) $0.78, down $0.77 year-over-year and $0.93 sequentially. The decrease was due to restructuring and other charges, unfavorable foreign exchange movements, and lower interest income.
Net Income Per Share (Non-GAAP) $2.61, up $0.26 year-over-year and $0.11 sequentially. The increase was due to operational efficiencies and favorable foreign exchange.
Free Cash Flow $169 million, calculated as cash flow from operations ($188.7 million) minus capital expenditures ($19.8 million).
iTero Lumina: New scanning technology with multi-direct capture technology, offering superior visualizations and effortless scanning. It represented over 90% of full system units in Q3.
Invisalign Palatal Expander: Continued rollout, offering a hygienic and comfortable alternative to traditional expanders, clinically effective for expansion.
ClinCheck Live Plan: Automates initial treatment plans in 15 minutes, enhancing efficiency and patient experience.
Exocad ART: Piloted in Europe, integrates orthodontics and restorative dentistry for better treatment outcomes.
Regional Growth: Double-digit Clear Aligner volume growth in APAC and EMEA regions, driven by teens, kids, and adults.
DSO Partnerships: Strong double-digit growth in EMEA and APAC regions, leveraging economies of scale and digital workflows.
Clear Aligner Volume: 648,000 cases in Q3, up 5% year-over-year, driven by international markets and teens/kids.
iTero Scanner Installations: Over 120,000 units globally, a 12% year-over-year increase.
AI-Powered Innovations: Investments in AI-powered treatment planning software and direct 3D printing of aligners to enhance efficiency and outcomes.
Localized Marketing: Focus on supporting doctors with localized marketing, education, and clinical support to navigate U.S. market headwinds.
North American Market Challenges: The orthodontic and dental markets in North America remain mixed, with softer performance in the North American retail doctor channel. This could impact revenue growth and market share in the region.
Systems and Services Revenue Decline: Q3 Systems and Services revenues were down year-over-year and sequentially, primarily due to seasonality and lower scanner system sales. This decline could affect overall profitability and growth in this segment.
Restructuring and Noncash Charges: The company incurred significant restructuring and noncash charges, including impairment on assets held for sale and excess inventory write-offs. These charges negatively impacted gross margins and operating income.
Foreign Exchange Fluctuations: Foreign exchange fluctuations have impacted revenues and gross margins, creating uncertainty in financial performance.
Product Mix Shift: A shift to lower-priced countries and products has led to a decrease in average selling prices for Clear Aligners, which could pressure margins.
Economic and Financial Barriers: Economic conditions and financial barriers for patients, particularly in North America, could limit the adoption of Invisalign treatments, despite efforts to increase affordability through partnerships.
Supply Chain and Inventory Challenges: Excess inventory write-offs and lower scanner wand sales indicate potential inefficiencies in supply chain and inventory management.
Regulatory and Tax Changes: Changes in U.K. VAT and U.S. tariffs have required adjustments in pricing and operations, adding complexity and potential cost pressures.
Q4 2025 Revenue: Expected to be in the range of $1.025 billion to $1.045 billion, up sequentially from Q3 2025.
Q4 2025 Clear Aligner Volume and ASP: Expected to increase sequentially due to favorable geographic mix.
Q4 2025 Systems and Services Revenue: Expected to increase sequentially, consistent with typical Q4 seasonality.
Q4 2025 GAAP Gross Margin: Expected to be 65.5% to 66%, up sequentially due to higher revenue and lower restructuring charges.
Q4 2025 Non-GAAP Gross Margin: Expected to be approximately 71%.
Q4 2025 GAAP Operating Margin: Expected to be 15.3% to 15.8%, up sequentially due to lower restructuring charges.
Q4 2025 Non-GAAP Operating Margin: Expected to be approximately 26%.
Fiscal 2025 Clear Aligner Volume Growth: Expected to grow mid-single digits.
Fiscal 2025 Revenue Growth: Expected to be flat to slightly up from 2024, assuming current foreign exchange rates.
Fiscal 2025 GAAP Operating Margin: Expected to be around 13.6% to 13.8%, down year-over-year due to restructuring and noncash charges.
Fiscal 2025 Non-GAAP Operating Margin: Expected to be slightly above 22.5%.
Fiscal 2025 Capital Expenditures: Expected to be approximately $100 million, primarily for technology upgrades.
Fiscal 2026 Operating Margin Improvement: Expected to improve by at least 100 basis points year-over-year due to restructuring actions and other initiatives.
Share Repurchase Program: During Q3, the company repurchased approximately 0.5 million shares of its common stock at an average share price of $136.77. These repurchases were made pursuant to the $200 million open market repurchase plan announced on August 5, 2025, which is expected to be completed in January of 2026. As of September 30, 2025, $928.4 million remains available for repurchase of common stock under the previously announced April 2025 repurchase program.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
